Thiazolidinediones, dyslipidaemia and insulin resistance syndrome

Current Opinion in Lipidology

Volumn 11, Issue 4, 2000, Pages 397-402

  Sunayama, Satoshi ^a   Watanabe, Yoshiro ^a   Daida, Hiroyuki ^a   Yamaguchi, Hiroshi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIC ACID DERIVATIVE; GLUCOSE; PIOGLITAZONE; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ATHEROGENESIS; CLINICAL TRIAL; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; META ANALYSIS; METABOLISM; PRIORITY JOURNAL; REVIEW;

CHROMANS; CLINICAL TRIALS; GLUCOSE; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; PHENOTYPE; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0033859573     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200008000-00009     Document Type: Review

References (87)

1. 1 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
2. 2 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
3. 3 Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009.
4. 4 Superko HR. Beyond LDL cholesterol reduction. Circulation 1996; 94:2351-2354.
5. 5 Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
6. 6 Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol 1996; 7:167-171.
7. 7 Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetes Med 1999; 16:179-192. A comprehensive review of thiazolidinediones is presented.
8. 8 Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997; 95:1-4.
9. 9 Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein pnenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:495-506.
10. 10 Sattar N, Petrie JR, Jaap AJ. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis 1998; 138:229-235.
11. 11 Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women, JAMA 1996; 276:875-881.
12. 12 Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276:882-888.
13. 13 Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95:69-75.
14. 14 Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-418. This study provides evidence that gemfibrozil therapy can reduce the cardiovascular risk associated with low HDL-cholesterol and hypertriglycaemia.
15. 15 Goldbourt U, Brunner D, Behar S, Reicher-Reiss H. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J 1998; 19(Suppl H):H42-H47.
16. 16 Watts GF, Dimmitt SB. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 1999; 10:561-574. A comprehensive review of fibrate therapy is presented, focusing on its potential cardiovascular benefits.
17. 17 Howard BV. Lipoprotein metabolism in diabetes. Curr Opin Lipidol 1994; 5:216-220.
18. 18 Taskinen MR. Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol 1995; 6:153-160.
19. 19 Garg A. Insulin resistance in the pathogenesis of dyslipidemia. Diabetes Care 1996; 19:387-389.
20. 20 Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Diabetes Care 1996; 19:390-393.
21. 21 Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989; 320:1060-1068.
22. 22 Santamarina-Fojo S, Dugi KA. Structure, function and role of lipoprotein lipase in lipoprotein metabolism. Curr Opin Lipidol 1994; 5:117-125.
23. 23 Olivecrona G, Olivecrona T. Triglyceride lipases and atherosclerosis. Curr Opin Lipidol 1995; 6:291-305.
24. 24 Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994; 5:339-349.
25. 25 Scheen AJ, Lefèbvre PJ. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999; 22:1568-1577. This is an excellent review of the antihyperglycaemic effect of troglitazone, describing the current status of thiazolidinediones in the treatment of type 2 diabetes.
26. 26 Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331:1188-1193.
27. 27 Antonucci T, Whitcomb R, McLain R, Lockwood D. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 1997; 20:188-193.
28. 28 Tack CJ, Smits P, Demacker PN, Stalenhoef AF. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998; 21:796-799.
29. 29 Sunayama S, Watanabe Y, Ohmura H, et al. Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis 1999; 146:187-193. This study describes lipidic effects of troglitazone in patients with insulin resistance syndrome.
30. 30 Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81:3299-3306.
31. 31 Izumino K, Sakamaki H, Ishibashi M, et al. Troglitazone ameliorates insulin resistance in patients with Werner's syndrome. J Clin Endocrinol Metab 1997; 82:2391-2395.
32. 32 Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15:193-203.
33. 33 Iwamoto Y, Kosaka K, Kuzuya T, et al. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19:151-156.
34. 34 Kumar S, Boulton AJ, Beck-Nielsen H, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia 1996; 39:701-709.
35. 35 Ghazzi MN, Ferez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997; 46:433-439.
36. 36 Sironi AM, Vichi S, Gastaldelli A, et al. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin Pharmacol Ther 1997; 62:194-202.
37. 37 Cörrea JCN, Hilsted J, Eckland D, et al. Investigation of twice or three times daily dose regimen of troglitazone, an insulin action enhancer, in patients with non insulin dependent diabetes mellitus. Eur J Clin Res 1997; 9:151-165.
38. 38 Horton ES, Whitehouse F, Ghazzi MN, et al. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care 1998; 21:1462-1469.
39. 39 Fonseca VA, Valiquett TR, Huang SM, et al. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J Clin Endocrinol Metab 1996; 83:3169-3176.
40. 40 Kumar S, Prange A, Schulze J, et al. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients. Diabetes Med 1998; 15:772-779.
41. 41 Iwamoto Y, Kosaka K, Kuzuya T, et al. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabetes Med 1996; 13:365-370.
42. 42 Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med 1998; 338:861-866.
43. 43 Buse JB, Gumbiner B, Mathias NP, et al. Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group. Diabetes Care 1998; 21:1455-1461.
44. 44 Hirano T, Yoshino G, Kazumi T. Troglitazone and small low-density lipoprotein in type 2 diabetes. Ann Intern Med 1998; 129:162-163.
45. 45 Shirai K, Itoh Y, Sasaki H, et al. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract 1999; 46:35-41. This study shows that troglitazone therapy increases LPL mass associated with an increase in LDL particle size in type 2 diabetic patients.
46. 46 Noguchi N, Sakai H, Kato Y, et al. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis 1996; 123:227-234.
47. 47 Cominacini L, Garbin U, Pastorino AM, et al. Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells. Diabetologia 1997; 40:165-172.
48. 48 Crawford RS, Mudaliar SR, Henry RR, Chait A. Inhibition of LDL oxidation in vitro but not ex vivo by troglitazone. Diabetes 1999; 48:783-790. This study describes the antioxidant property of troglitazone.
49. 49 Cominacini L, Young MM, Capriati A, et al. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers. Diabetologia 1997; 40:1211-1218.
50. 50 Cominacini L, Garbin U, Fratta Pasini A, et al. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes 1998; 47:130133.
51. 51 Matsumoto K, Miyake S, Yano M, et al. Increase of lipoprotein (a) with troglitazone. Lancet 1997; 350:1748-1749.
52. 52 Ovalle F, Bell DS. Troglitazone's effect on lipoprotein(a) levels. Diabetes Care 1999; 22:859-860.
53. 53 Kelly IE, Man TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22:288-293. This study reports that treatment with troglitazone in patients with type 2 diabetes decreases intra-abdominal fat mass, but does not affect total body fat or weight.
54. 54 Mori Y, Murakawa Y, Okada K, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999; 22:908-912. This study reports that troglitazone therapy selectively reduced visceral fat in type 2 diabetic patients.
55. 55 Kawai T, Takei I, Oguma Y, et al. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 1999; 48:1102-1107. This study shows the difference in the response to troglitazone between subcutaneous and visceral adipose tissue in type 2 diabetic persons.
56. 56 Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987; 36:54-59.
57. 57 Ogihara T, Rakugi H, Ikegami H, et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8:316-320.
58. 58 Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21:2135-2139.
59. 59 Fonseca VA, Reynolds T, Hemphill D, et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998; 12:181-186.
60. 60 Ishizuka T, Itaya S, Wada H, et al. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes 1998; 47:1494-1500.
61. 61 Ebeling P, Teppo AM, Koistinen HA, et al. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes. Diabetologia 1999; 42:1433-1438. This study shows that troglitazone may reduce some acute-phase proteins in type 2 diabetic persons. This finding is interesting because inflammation has been suggested to play a role in both insulin resistance and atherosclerosis.
62. 62 Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47:507-514.
63. 63 Martin G, Schoonjans K, Staels B, Auwerx J. PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 1998; 137(Suppl-1):S75-S80.
64. 64 Kaumi T, Hirano T, Odaka H, et al. VLDL triglyceride kinetics in Wistar fatty rats, an animal model of NIDDM: effects of dietary fructose alone or in combination with pioglitazone. Diabetes 1996; 45:806-811.
65. 65 Burant CF, Sreenan S, Hirano K, et al. Troglitazone action is independent of adipose tissue. J Clin Invest 1997; 100:2900-2908.
66. 66 Kobayashi J, Nagashima I, Hikita M, et al. Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Br J Clin Pharmacol 1999; 47:433-439. This study shows an increase in LPL mass associated with troglitazone therapy, and confirms this clinical finding experimentally.
67. 67 Schoonjans K, Peinado-Onsurbe J, Lefèbvre AM, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15:5336-5348.
68. 68 Lefèbvre AM, Peinado-Onsurbe J, Leitersdorf I, et al. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol 1997; 17:1756-1764.
69. 69 Wang M, Wise SC, Leff T, Su TZ. Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma. Diabetes 1999; 48:254-260. Direct inhibitory effect of several thiazolidinediones on cholesterol biosynthesis was examined in vitro. This effect was neither related to ligand affinity nor inhibited by PPAR-γ blockade. The authors concluded that inhibition of cholesterol biosynthesis may be through a non-PPAR-γ mediated mechanism.
70. 70 Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338:916-917.
71. 71 Imura H. A novel antidiabetic drug, troglitazone: reason for hope and concern. N Engl J Med 1998; 338:908-909.
72. 72 The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999; 22:623-634.
73. 73 Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000; 132:118-121.
74. 74 Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med 2000; 132:121-124.
75. 75 Kallen CB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 1996; 93:5793-5796.
76. 76 Zhang B, Graziano MP, Doebber TW, et al. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 1996; 271:9455-9459.
77. 77 De Vos P, Lefébvre AM, Miller SG, et al. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 1996; 98:1004-1009.
78. 78 Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998; 101:1354-1361.
79. 79 Auwerx J, Staels B. Leptin. Lancet 1998; 351:737-742.
80. 80 Shimizu H, Tsuchiya T, Sato N, et al. Troglitajone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 1998; 21:1470-1474.
81. 81 Nolan JJ, Olefsky JM, Nyce MR, et al. Effect of troglitazone on leptin production. Studies in vitro and in human subjects. Diabetes 1996; 45:1276-1278.
82. 82 Mantzoros CS, Dunaif A, Flier JS. Leptin concentrations in the polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:1687-1691.
83. 83 Tontonoz P, Nagy L. Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor gamma: implications for cardiovascular disease. Curr Opin Lipidol 1999; 10:485-490. This is an up-to-date review of the effects of PPAR-γ activators on vascular wall, including possible proatherogenic effects.
84. 84 Nagy L, Tontonoz P, Alvarez JG, et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93:229-240.
85. 85 Tontonoz P, Nagy L, Alvarez JG, et al. PPARgamma promotes monocyte/ macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93:241-252.
86. 86 Shiomi M, Ito T, Tsukada T, et al. Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase. shows a synergistic effect on atherosclerosis of WHHL rabbits. Atherosclerosis 1999; 1 42:345-353. This experimental study suggests a synergistic antiatherogenic effect of β-hydroxy-β-methylglutaryl coenzyme A reductase inhibitor and troglitazone in hypercholesterolaemic patients with insulin resistance.
87. 87 Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83:1818-1820.